Skip to content
06/16/2026
  • Biotech Tools Hub
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Our Profile on PRLog
Merlintrader Trading Pub

Merlintrader Trading Pub

Biotech catalyst news and analysis. FDA PDUFA tracker

DISCLAIMER — Educational content only. Not financial advice. Stocks can be volatile and may cause capital loss.
Read Disclaimer
Primary Menu
  • Merlintrader
    • About Merlintrader
    • Merlintrader Blog
    • Daily Briefing
    • Daily Watchlist
    • Discord
    • Latest News
    • Small & Medium Caps
    • CHARTSWATCHER 10% OFF !
    • Disclaimer
  • Cannabis Stocks Hub 2026
    • Cannabis Stocks HUB 2026: A Possible Reset for a Broken Sector $MSOS, $TLRY, $CGC, $CRON, $ACB
    • Tilray Brands (Nasdaq: $TLRY): Cannabis, Beverage and Medical Cannabis Stock Hub
  • Space, Defense & AI Hub 2026
    • BlackSky Technology Inc. (NYSE: $BKSY) Stock Hub
    • BigBear.ai Holdings (NYSE: $BBAI)
    • Castellum, Inc. (NYSE American: $CTM) Stock Hub
    • Intuitive Machines (Nasdaq: $LUNR) Stock Hub
    • Ondas Holdings (NASDAQ: $ONDS) Stock Hub
    • Palladyne AI Corp. (Nasdaq: $PDYN) Stock Hub
    • Planet Labs PBC (NYSE: $PL)
    • POET Technologies (NASDAQ: $POET): Company Story,
    • Red Cat Holdings (NASDAQ: $RCAT)
    • Redwire Corporation (NYSE: $RDW) Stock Hub
    • Rocket Lab Corporation (Nasdaq: $RKLB) Stock Hub
    • Satellogic Inc. (Nasdaq: $SATL)
  • Biotech Stocks Hub
    • ADMA Biologics (Nasdaq: $ADMA)
    • Agios Pharmaceuticals (Nasdaq: $AGIO) Stock Hub
    • Alpha Tau Medical Ltd. (Nasdaq: $DRTS)
    • Altimmune Inc. (Nasdaq: $ALT )
    • Aquestive Therapeutics (Nasdaq: $AQST Stock Hub.
    • Ardelyx, Inc. (Nasdaq: $ARDX) Stock Hub
    • BioCryst Pharmaceuticals (Nasdaq: $BCRX) Stock Hub
    • Capricor Therapeutics (Nasdaq: $CAPR) Stock Hub
    • Corcept Therapeutics $CORT Stock Hub
    • CorMedix Therapeutics (Nasdaq: $CRMD) Stock Hub
    • Cytokinetics, Incorporated (Nasdaq: $CYTK)
    • Fate Therapeutics (Nasdaq: $FATE): Stock Hub
    • Geron Corporation (Nasdaq: $GERN) Stock Hub
    • ImmunityBio, Inc. (Nasdaq: $IBRX) Stock Hub
    • Iovance Biotherapeutics (Nasdaq: $IOVA)
    • MannKind Corporation (Nasdaq: $MNKD) Stock Hub
    • Microbot Medical Inc. (Nasdaq: $MBOT) Stock Hub
    • Moleculin Biotech (Nasdaq: $MBRX) Stock Hub
    • Novavax, Inc. (Nasdaq: $NVAX) Stock Hub
    • NRx Pharmaceuticals (Nasdaq: $NRXP) Stock Hub
    • Ocugen, Inc. (Nasdaq: $OCGN) Stock Hub
    • Ocular Therapeutix (Nasdaq: $OCUL) Stock Hub
    • Omeros Corporation (Nasdaq: $OMER): Stock Hub
    • Outlook Therapeutics (Nasdaq: $OTLK): Stock Hub
    • Protalix BioTherapeutics (NYSE American: $PLX) Stock Hub
    • SeaStar Medical Holding Corporation (Nasdaq: $ICU) Stock Hub
    • SELLAS Life Sciences Group (Nasdaq: $SLS) Stock Hub.
    • Summit Therapeutics (Nasdaq: $SMMT) Stock Hub
    • Travere Therapeutics (Nasdaq: $TVTX)
    • Viridian Therapeutics (Nasdaq: $VRDN)
  • FREE CATALYST CALENDAR
    • Catalyst Total Tracker
  • Merlintrader Travel Pub

Home - Uncategorized - The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question

  • Uncategorized

The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question

To understand the weight of the diplomatic turn announced between June 14 and June 15, it is necessary to go back to late February 2026, when the United States and Israel launched a military campaign against Iran. From that point, the conflict turned the Strait of Hormuz from a latent geopolitical risk into a central variable for oil, gas, inflation, interest rates and global equity markets.
1 hour ago (Last updated: 1 hour ago) 6 views
truce Usa Iran
Geopolitical Analysis & Markets — June 15, 2026

The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question

Washington and Tehran have reached a memorandum of understanding aimed at halting the war, reopening the Strait of Hormuz over time and moving the most difficult files into a new negotiating phase. Markets reacted immediately: oil fell sharply, European gas eased, energy shares came under pressure and Europe’s STOXX 600 moved into record territory. But this is not a clean peace settlement. The nuclear question remains unresolved, Israel is outside the arrangement, Iran’s internal power structure is still adjusting after months of war, and the real market test will be implementation rather than the announcement itself.

Merlintrader — merlintrader.com Published: June 15, 2026 Category: Geopolitics & Markets
Next key event
Formal ceremony — Switzerland
Friday, June 19, 2026
Important point
The MOU has already been signed/approved; the ceremony is expected to formalize the political step.
Initial framework: 60-day truce and follow-on technical negotiations.
Brent Crude
$83.17
-4.76%
WTI Crude
$80.75
-4.87%
European Gas TTF
€42.48
€/MWh, below 45
STOXX 600
638.53
+0.9% — new all-time high
Europe
Risk-on
autos, banks and cyclicals in focus
Residual risk
High
nuclear, Israel, IRGC, Hormuz

Why This Matters Now

The U.S.-Iran memorandum matters because it attacks the single most important pressure point of the last several months: the perception that the Strait of Hormuz could remain blocked, militarized or only partially usable for an extended period. In market terms, Hormuz was not just a geographic choke point. It became a pricing mechanism for crude oil, European gas, inflation expectations, central-bank policy and the risk appetite behind global equities.

The first reaction was therefore logical. When the market sees even a credible path toward renewed traffic through Hormuz, it starts removing part of the war premium from energy prices. That does not mean the crisis is over. It means traders are repricing probability. The probability of an immediate supply shock has fallen, while the probability of a negotiated normalization path has increased.

That distinction is critical. A true peace agreement would close the file. This deal does not. It freezes the most dangerous military phase, opens a 60-day diplomatic window and shifts the burden from battlefield escalation to execution, monitoring and political discipline. For investors, that is enough to move markets, but not enough to eliminate risk.

How We Got Here: Almost Four Months of War and a Still-Fragile Truce

To understand the weight of the diplomatic turn announced between June 14 and June 15, it is necessary to go back to late February 2026, when the United States and Israel launched a major military campaign against Iran. From that point, the conflict turned the Strait of Hormuz from a background geopolitical risk into a front-line variable for energy markets and global risk sentiment.

The war changed the region’s balance in three ways. First, it exposed how quickly the energy system can become hostage to naval chokepoints. Second, it showed that direct U.S. and Israeli pressure could inflict serious damage without necessarily forcing Iran to fully capitulate. Third, it pushed Gulf states, European governments and global investors to reconsider the cost of a prolonged regional conflict.

The death of Supreme Leader Ali Khamenei during the strikes marked a historic fracture inside Iran’s power structure. The Iranian system did not collapse, but it was forced to reorganize under extreme conditions: military pressure, economic isolation, disrupted energy flows, internal political uncertainty and rising tension across the wider regional proxy map.

That internal context matters. Iran enters the agreement not as a defeated state formally surrendering its strategic program, but as a damaged, pressured and still dangerous regional actor looking for breathing space. Washington, in turn, can present the framework as a way to stop the war, reduce energy risk and move the nuclear file into a controlled negotiating channel. Both sides can claim something. Neither side has secured everything.

Mediation by Pakistan and Qatar played a central role. Islamabad served as a political bridge between Washington and Tehran, while Doha maintained operational channels during the most delicate phases. This kind of mediation matters because neither side wanted to appear weak, and neither side could easily move directly from confrontation to compromise without an intermediary architecture.

The result is not a comprehensive peace settlement. It is a memorandum of understanding designed to freeze the conflict, restart flows through a strategic waterway and move the hardest questions into a subsequent negotiation. That is why the market reaction can be optimistic while the strategic reading remains cautious.

Key Points of the Agreement

The full text of the memorandum has not been fully absorbed by markets in a legal-document sense, but the reported framework points to a clear political structure: an initial ceasefire period, gradual reopening of Hormuz, conditional economic relief and later negotiations on Iran’s nuclear program, sanctions and verification.

Initial 60-day truce

The operational core of the agreement is a 60-day de-escalation window. This is not the same as a definitive peace. It is a testing period during which the parties must show that the ceasefire can hold under pressure.

Gradual reopening of Hormuz

The Strait is expected to become progressively more accessible to commercial traffic, but normalization requires naval coordination, insurance confidence, safe passage guarantees and technical time.

Conditional economic relief

Relief for Iran is not a blank check. Any meaningful easing of sanctions, asset restrictions or oil-export pressure remains tied to cooperation and the broader diplomatic track.

Nuclear file deferred

Iran’s nuclear program remains the central unresolved issue. The agreement appears to move the question into follow-on talks rather than solving it immediately.

From a market perspective, the Hormuz component is the easiest to price. If shipping volumes rise and insurance premia fall, crude oil should continue to lose part of its geopolitical premium. The nuclear component is harder. It is slower, more political, more technical and more likely to become the place where the agreement faces its first serious stress test.

The most important thing for readers is not to confuse “deal announced” with “risk eliminated.” The agreement reduces the probability of near-term escalation. It does not eliminate the possibility of future breakdown. It changes the market’s base case, but it does not remove the tail risk.

Merlintrader reading

This is best understood as a market-moving truce, not a final peace architecture. The agreement is bullish for risk sentiment only as long as physical flows, political discipline and technical negotiations move in the same direction.

The Actors: Who Really Won?

Every major actor is trying to frame the agreement as a victory. Washington can say it forced a diplomatic opening while reducing energy risk. Tehran can say it survived the campaign without surrendering its strategic identity. Pakistan and Qatar can claim the role of indispensable mediators. Europe can welcome lower energy stress. Gulf states can breathe after months of exposure to retaliation risk.

USA
Donald Trump
President of the United States; political sponsor of the agreement.
USA
JD Vance
Vice President; involved in signing/approving the MOU.
Iran
Mohammad Bagher Qalibaf
Speaker of Iran’s parliament; central figure in the negotiating step.
Iran
Abbas Araghchi
Foreign Minister; diplomatic reference point on the file.
Mediators
Pakistan & Qatar
Political and operational channels between the parties.
Italy / Europe
Giorgia Meloni / E4
Focus on free navigation, non-proliferation and energy stability.

The United States gets a near-term reduction in oil-market pressure and a way to claim strategic success without extending the war indefinitely. For Washington, this matters domestically and internationally. A prolonged conflict around Hormuz would have carried inflation risk, military cost and political exposure. A framework that reopens shipping while preserving pressure on the nuclear file is easier to sell.

Iran gets time. That may be the most important word in the entire agreement. Time to stabilize internal politics, time to rebuild economic channels, time to test sanctions relief, time to manage public expectations and time to reposition after a damaging conflict. But time is not the same as victory. Tehran still faces a battered economy, domestic frustration and a hardline security establishment that may resist concessions.

Europe gets relief through lower energy stress. That does not mean Europe controls the process. It means Europe benefits if the process works. For the European economy, the most direct channel is inflation. Lower crude, lower gas and lower transportation stress reduce pressure on households, industrial margins and central-bank policy.

The agreement is good news because it lowers immediate risk. But it should not be confused with a definitive solution: the real test begins now, as the parties must turn a political truce into verifiable normalization. — Merlintrader editorial view

Italy’s position fits this wider European logic. Rome has indicated willingness to support an international presence for maritime security, within the framework of authorizations and allied coordination. That is not a minor detail. If the Strait of Hormuz is the energy artery, then freedom of navigation becomes a market variable, not just a diplomatic slogan.

The Market Reaction: Oil Down, Equities Up

The market reaction was unusually clean: oil fell, European gas eased, energy shares weakened and broad equity indices rallied. This is exactly the pattern one would expect when a geopolitical supply premium starts to come out of energy prices.

Energy — geopolitical premium retreats

Brent Crude -4.76% to $83.17
WTI Crude -4.87% to $80.75
European Gas TTF about €42.48/MWh
Energy equities oil majors under pressure

Equities — relief rally

STOXX 600 about +0.9% — 638.53
Europe record territory
Autos / travel / cyclicals benefit from lower energy costs
Volatility lower

The crude move is the central market signal. During the conflict, traders had to price the possibility that a significant share of global energy flows could remain blocked, delayed or vulnerable to military disruption. The deal reduces that risk. It does not eliminate it, but it lowers the immediate probability of a supply shock.

That is why the response in energy equities was different from the response in broad indices. Oil producers and energy majors may suffer when crude falls sharply, especially if part of the decline reflects a reduction in geopolitical premium rather than a demand boom. At the same time, lower oil can be supportive for airlines, transport companies, industrials, consumer stocks and economies exposed to imported energy.

European equities were especially sensitive because Europe had absorbed the conflict through several channels at once: higher energy costs, weaker industrial confidence, pressure on household purchasing power and uncertainty over central-bank policy. A credible path toward lower energy prices therefore supports the idea that inflation pressure may ease faster than previously expected.

But the rally also has a vulnerability. If the market moves too quickly from “risk reduced” to “risk gone,” it can become exposed to any negative headline: an Israeli response, an IRGC provocation, a failed inspection track, a shipping incident, a mine-clearance delay, or a disagreement over sanctions sequencing.

Why Hormuz Is the Real Market Trigger

The Strait of Hormuz is not just another regional waterway. It is one of the most important energy corridors on the planet. When Hormuz becomes unstable, the market does not simply price today’s lost barrels. It prices uncertainty around tomorrow’s insurance, shipping schedules, military escorts, refinery planning and emergency reserves.

That is why even partial normalization can matter. If tankers can move with credible guarantees, insurers lower risk premia, charterers regain confidence and buyers can plan forward supply with less panic. The price impact can be larger than the immediate physical-flow change because markets discount future conditions.

The opposite is also true. A single incident in the Strait could reverse sentiment quickly. Shipping markets are extremely sensitive to perceived safety. If there are mines, missile threats, drone attacks, naval warnings or unclear rules of engagement, the cost of moving oil can rise even if the Strait is technically open.

For that reason, the market will watch physical indicators more than speeches: vessel tracking, insurance rates, port departures, naval coordination, official guidance from Gulf states and the behavior of commercial operators. The deal can move prices today. The shipping data will decide whether that move is sustainable.

Shadows Over the Deal: Why It Is Not Over Yet

Markets always tend to anticipate. When positive news arrives, price moves ahead of facts. But in the Middle East, the distance between announcement, implementation and stability can be enormous. In this case, there are at least four residual variables.

Open issues and residual risks

Israel is not part of the agreement. The Israeli government has received the agreement coldly and retains its freedom of action, especially regarding Hezbollah, Lebanon and Iran’s nuclear program. This is the most immediate geopolitical risk because Israel may judge the nuclear file by different standards than Washington.
The IRGC remains an internal variable. The Revolutionary Guards have deep economic, military and ideological interests in Iran’s regional posture. Even with a political agreement, internal discipline inside the Iranian system is not guaranteed.
The nuclear file has been deferred, not resolved. The decisive point will be verification: uranium stockpiles, inspector access, timing, international supervision and real enforcement capacity. Without this, the truce remains vulnerable.
Hormuz does not return to normal in one day. Reopening requires naval security, coordination with Oman and Iran, traffic management, removal of operational risks where needed and commercial insurers willing to return to high-risk routes.

The nuclear issue is the most important strategic gap. If Iran’s enriched uranium stockpiles, inspection access and missile capabilities remain vague, the agreement can survive for a few weeks while markets celebrate, but it may struggle to become durable. Investors should therefore separate the short-term energy relief from the longer-term strategic risk.

The IRGC issue is equally important because states do not always behave as unitary actors during post-war transitions. Political leaders may accept a framework, while hardline military, intelligence or ideological factions may see the deal as a threat to their leverage. That does not mean sabotage is inevitable. It means implementation risk is real.

What This Means for Europe

Europe is one of the clearest beneficiaries if the agreement holds. The continent is structurally exposed to imported energy, industrial input costs and confidence shocks. Lower oil and gas prices can ease inflation pressure, support consumer purchasing power and reduce the squeeze on energy-intensive industries.

The market reaction in European equities reflects that logic. A lower energy-risk premium supports autos, travel, banks, industrials and selected consumer names. It can also support the broader argument that the European Central Bank and other policymakers may face less pressure from imported inflation.

But Europe’s upside is conditional. If Hormuz normalizes only partially, if shipping remains expensive, or if the nuclear track breaks down, the continent can quickly lose part of that relief. The European rally is not simply a celebration of diplomacy. It is a repricing of energy risk.

Italy’s possible role in a naval mission is especially relevant because it shows that the agreement may require an international security architecture, not just signatures. Freedom of navigation has to be enforced, monitored and made credible for commercial operators.

Outlook: What to Watch in the Coming Weeks

The most honest analysis must hold two ideas together. First: the agreement is genuinely positive news, because it reduces a systemic risk that had been weighing on energy, inflation and confidence. Second: the market may already have priced the easy part of the story, meaning the announcement. Now the hard part begins: implementation.

Positive scenario

The formal ceremony proceeds without incident, Hormuz reopens gradually but credibly, insurance premia decline, energy flows improve and the nuclear file moves into a verifiable negotiation. In this scenario, oil and gas remain under pressure and European equities consolidate record territory.

Risk scenario

Israel maintains or intensifies operations, the IRGC obstructs the truce, Hormuz reopens only partially or the nuclear file immediately stalls. In this scenario, oil can quickly recover part of the decline, volatility rises again and the equity rally loses strength.

For markets, the key word now is verification. It is not enough for the memorandum to exist. Investors need to see ships, flows, insurance, sanctions, nuclear talks and the behavior of actors excluded from the agreement. The rally says the market wants to believe in de-escalation. Prudence says the region has already shown many times how quickly a diplomatic window can close.

Key indicators to monitor

The next useful signals are vessel traffic through Hormuz, shipping insurance costs, statements from Israel, inspection language around the nuclear file, Iranian domestic reaction, sanctions sequencing, and whether European governments move from political support to concrete maritime-security commitments.

Merlintrader Bottom Line

The U.S.-Iran deal is important because it changes the market’s immediate risk map. It lowers the probability of an extended Hormuz shock, removes part of the energy premium and gives equities a reason to rally. But it does not remove the structural problems that created the crisis.

The right reading is neither blind optimism nor automatic skepticism. The deal is meaningful. The market reaction is understandable. The oil move is coherent. The European equity rally has a macro logic. But the unresolved nuclear file, Israel’s position, Iran’s internal hardliners and the operational reality of reopening Hormuz all remain live variables.

For traders and investors, this is a classic transition from headline risk to execution risk. The first headline moved prices. The next phase will be slower, more technical and more vulnerable to reversals. That is where the real signal will appear.

Main Sources and Related Reading

Information on the U.S.-Iran memorandum, the 60-day truce, the gradual reopening of the Strait of Hormuz, the European market reaction, oil, gas and possible Italian participation in an international naval mission was checked against Reuters and ANSA. Market data refers to updates available on June 15, 2026.

Reuters — U.S. officials say Iran pact signed, Hormuz traffic will rise significantly
Reuters — U.S., Iran reach preliminary agreement to end war, signing set for Friday
Reuters — Gulf recalibrates as Iran emerges intact from war
Reuters — With war likely over, Iranian rulers face domestic demands
Reuters — Europe’s STOXX 600 hits all-time high
Reuters — Oil hits three-month low as U.S. and Iran reach deal to reopen Strait of Hormuz
Reuters — Energy shares fall as Iran deal lowers Hormuz disruption risk
Reuters — Citi cuts Brent forecasts as U.S.-Iran MOU points to Hormuz flow normalization
ANSA — Italy willing to take part in Strait of Hormuz naval mission

More from Merlintrader

For more updates on markets, geopolitics, energy, small-mid caps, biotech catalysts and macro scenarios, visit the Merlintrader blog.

Merlintrader.com — Blog
Merlintrader.com — Disclaimer
Merlintrader.com — Privacy & Terms

Disclaimer — legal notice

This article is provided strictly for informational, educational and editorial purposes. It does not constitute investment advice or a recommendation to buy or sell any security, ETF, commodity, currency, bond or other financial instrument. The author is not acting as a licensed financial advisor. Any investment decision should be preceded by an independent assessment and, where appropriate, the opinion of a qualified professional. Merlintrader may hold positions in the instruments mentioned. Full disclaimer: merlintrader.com/disclaimer

Content prepared with attention to the distinction between verified facts, market data, scenario analysis and editorial interpretation.

Merlintrader.com — June 15, 2026 Blog Disclaimer Privacy & Terms Informational content — not financial advice

What do you feel about this?

  • Uncategorized

Post navigation

Previous: Celldex Therapeutics — Barzolvolimab, Mast Cells and the Revolution in Chronic Urticaria Treatmen

Related Stories

Short
  • Uncategorized

Short Squeeze Watch: three crowded short-interest stocks, but not the same setup

2 days ago 16
KPTI
  • Uncategorized
  • Reports Biotech

Karyopharm’s ASCO Moment: Can a Mixed Phase 3 Still Become a Myelofibrosis Story? $KPTI

3 weeks ago 2
  • Uncategorized
  • RKLB

Wall Street weekly recap and next-week setup: $PLTR, $AMD, $RKLB lead a catalyst-heavy watchlist as AI earnings, cannabis policy and space-defense names move back into focus

1 month ago 1
  • TVTX
  • Uncategorized

Travere Therapeutics ( $TVTX ) after FILSPARI’s FDA approval in FSGS

1 month ago 1
  • Uncategorized

Kodiak Sciences ( $KOD ): GLOW2 hits cleanly, Zenkuda clears the second major diabetic retinopathy hurdle

3 months ago 2
  • Uncategorized

Artelo Biosciences ( $ARTL ) — Final March 2026 Update: hard Nasdaq deadline, fragile balance sheet, and a real separation between pipeline promise and financing reality

3 months ago 2

Trending Now

The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question truce Usa Iran 1
  • Uncategorized

The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question

1 hour ago 6
Celldex Therapeutics — Barzolvolimab, Mast Cells and the Revolution in Chronic Urticaria Treatmen cldx 2
  • Reports Biotech

Celldex Therapeutics — Barzolvolimab, Mast Cells and the Revolution in Chronic Urticaria Treatmen

3 hours ago 40
Neumora Therapeutics (Nasdaq: $NMRA): Navacaprant Is Over, the Platform Story Moves to NMRA-511, NMRA-898 and NMRA-215 nmra 3
  • Reports Biotech

Neumora Therapeutics (Nasdaq: $NMRA): Navacaprant Is Over, the Platform Story Moves to NMRA-511, NMRA-898 and NMRA-215

5 hours ago 42
Amylyx Pharmaceuticals (Nasdaq: $AMLX) — Avexitide, Post-Bariatric Hypoglycemia and the LUCIDITY Phase 3 Trial AMLX 4
  • Reports Biotech

Amylyx Pharmaceuticals (Nasdaq: $AMLX) — Avexitide, Post-Bariatric Hypoglycemia and the LUCIDITY Phase 3 Trial

8 hours ago 63

Welcome to Merlintrader!
Here we share ideas, analysis and news from the biotech and small-cap world, with a special focus on the catalysts that really move the market.
If you like the content on this site, please help me by sharing it on social media and in other forums. Thank you!

✦ Disclaimer: The information provided is strictly for educational and informational purposes. This content represents independent, informational research and does not constitute regulated investment research or financial advice. I am not a licensed financial advisor or an authorized investment professional. Nothing here should be interpreted as a recommendation to buy, sell, or trade any security. If you need personalized financial advice, you should consult a qualified and authorized professional. Biotech and small-cap stocks carry significant risk, including the potential loss of all invested capital. Each user remains fully responsible for their own trading decisions. Full legal disclaimers.
✦ RunUP Biotech: Interested in understanding market dynamics around FDA catalysts and clinical trials? The RunUP Biotech strategy provides a framework for analyzing pre-event positioning, volume patterns, and risk-management approaches. Educational focus on probability and pattern structure — not predictions or guaranteed outcomes. Learn more →
✦ Support Merlintrader: This website is free and has no paywall. If you find the reports and tools useful, you can support the project via Buy Me a Coffee — it helps me cover costs and keep publishing independent analysis.
✦ Disclosure: I closed my DRTS position today, May 11, at $10.29 per share, after entering at $7.31 per share. I opened a small position in CING on May 12 at $4.90 per share. Read the full disclaimer.
```
Free research library

Explore the Merlintrader blog

Inside the site you will find hundreds of free reports, deep dives on biotech and small caps, FDA catalyst coverage, market analysis, and articles built to help readers understand what really moves these stocks.

  • Full reports on individual stocks
  • FDA, catalyst and clinical-trial analysis
  • Daily briefings, watchlists and market themes
  • A free archive updated on a regular basis
Explore the blog

Free content, readable structure, and regular updates.

Archivio gratuito

Esplora il blog Merlintrader

Nel sito trovi centinaia di report gratuiti, approfondimenti su biotech e small cap, catalyst FDA, analisi di mercato e articoli pensati per aiutare i lettori a capire meglio cosa muove davvero questi titoli.

  • Report completi su singoli titoli
  • Analisi di catalyst, FDA e trial clinici
  • Daily briefing, watchlist e temi di mercato
  • Un archivio gratuito aggiornato con regolarità
Vai al blog

Contenuti gratuiti, struttura leggibile e aggiornamenti costanti.

Merlintrader Newsletter

Stay ahead of the next catalyst

Get market notes, deep-dive updates and catalyst-focused research directly from Merlintrader.

Educational market content only. No spam. You can unsubscribe anytime.
Terms, privacy and disclaimer

You May Have Missed

truce Usa Iran
  • Uncategorized

The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question

1 hour ago 6
cldx
  • Reports Biotech

Celldex Therapeutics — Barzolvolimab, Mast Cells and the Revolution in Chronic Urticaria Treatmen

3 hours ago 40
nmra
  • Reports Biotech

Neumora Therapeutics (Nasdaq: $NMRA): Navacaprant Is Over, the Platform Story Moves to NMRA-511, NMRA-898 and NMRA-215

5 hours ago 42
AMLX
  • Reports Biotech

Amylyx Pharmaceuticals (Nasdaq: $AMLX) — Avexitide, Post-Bariatric Hypoglycemia and the LUCIDITY Phase 3 Trial

8 hours ago 63
Scanner for active traders
ChartsWatcher logo

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

ChartsWatcher platform screenshot
Recommended platform
Medved Trader logo

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Medved Trader platform dashboard
Merlintrader author

Authors: Merlintrader, Jane and Gemini

Author's note

In every piece of content I share things as I personally interpret them, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants (Jane and Gemini), which help me organise data, cross-check details and improve charts or visuals. However, any interpretation, opinion and final judgement remain entirely my own as a trader like you, not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If you spot something that looks off, feel free to let me know and I will correct it. Please do not treat this content as professional investment advice, but as one more piece of information to compare with your own research and the opinion of qualified professionals.

Donate via PayPal

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs so that the content can remain independent and freely accessible.

Buy Me a Coffee

Tools and research platforms used by Merlintrader

Below is a shortlist of tools and platforms that I personally use to follow prices, catalysts, fundamentals and sentiment. Links are provided for transparency and convenience only.

  • Finviz Elite – advanced stock screener and charting, used for heatmaps, relative performance and technical context.
  • ChartsWatcher – real-time, next-generation scanner for the US stock market. Used to monitor intraday momentum, volume spikes and colour-coded pattern alerts.
  • Stocktwits – social stream focused on tickers, used only as a sentiment and activity indicator, not as a source of investment recommendations.
  • Monica.im – AI assistant used for light reports, drafting and quick research; helps with structuring notes and first-pass analysis alongside the deep-dive work published on Merlintrader.
  • Medved Trader – professional trading and charting platform used for real-time execution, order-flow and detailed intraday analysis. No affiliate link; mentioned because it is part of the actual trading workflow.
  • Merlintrader trading Blog – the home for biotech-focused reports, dashboards and educational articles that expand on the ideas mentioned in this document.

AI usage disclosure

Content on Merlintrader may be prepared using a human + AI workflow. Drafting, editing and data organisation may be supported by generative AI tools, for example large language models provided by third-party vendors, based on prompts and instructions defined by the author. All sources are publicly available, and the final selection of data, checks, opinions and conclusions is carried out by the author, who remains fully responsible for the content.

Monica.im Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Legal disclaimer – please read carefully

Each piece of content is provided strictly for informational and educational purposes. It is not and must not be interpreted as investment advice, investment research in a regulatory sense, portfolio management, or a recommendation to buy or sell any security or financial instrument. The author is not a licensed investment advisor, not a registered broker, and not a FINRA/SEC-registered analyst or portfolio manager. Any reference to potential scenarios, price levels or catalysts is purely illustrative and reflects a personal, non-professional view based on publicly available information at the time of writing.

Nothing in any content published on Merlintrader should be considered a solicitation to the public to invest, nor an invitation to raise capital, nor a promise of profit or of capital protection. Biotech and healthcare stocks in particular can be highly volatile and speculative, especially around clinical and regulatory catalysts. Before making any investment or trading decision, always perform your own due diligence and consider consulting a qualified, regulated financial professional who can evaluate your personal situation, objectives and risk tolerance. Past performance and historical examples do not guarantee future results.

The author may hold, or may have held, long or short positions in some of the securities mentioned in Merlintrader content, and may open, close or modify such positions without notice. This potential alignment of interests may influence the tone or focus of the analysis. No position held by the author changes the fact that this content is not investment advice and should not be used as such.

Biotech Catalyst Calendar

For a broader, continuously updated view of upcoming biotech catalysts (PDUFA dates, major clinical readouts, regulatory events and key conferences), you can consult the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar

Terms and Conditions
Cookie Policy
Privacy Policy
Merlintrader is a personal blog curated by Horacio F. Greco. Contact: info@merlintrader.com. No professional financial advice.
Do Not Sell or Share My Personal Information
  • Policies, Terms and Conditions
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Our Profile on PRLog
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.